Spotlight On... EarlySense launches patient monitoring tech to detect sepsis in non-ICU patients; Trinity Medical acquires neonatal disposable devices; Indicted CEO James Mazzo requests stay of insider trading trial; and more...

Waltham, MA's EarlySense has added a new feature to its contact-free continuous patient monitors. It says the Multi-Parameter Alert capability monitors patient heart and respiratory rate to spot changes that could be a sign of an adverse event during hospital stays, such as sepsis, which is often deadly if not detected early. "Non-ICU patients are at risk for a variety of complications during hospitalization and early warning signs are often subtle and not easily detected," said EarlySense CEO Avner Halperin. "By providing healthcare professionals with continuous data and timely indication of change through our Multi-Parameter Alert, precious time can be saved enabling early detection and treatment of Sepsis as well as other potential adverse events." More

@FierceMedDev: IYCMI: Theranos slammed again after new study points to testing flaws. Article | Follow @FierceMedDev

@EmilyWFierce: UPDATED: Astellas cancer med Xtandi draws fire as U.S. lawmakers demand a pricing hearing. FiercePharma story | Follow @EmilyWFierce

> Trinity Medical Devices has purchased CAS Medical Systems' line of neonatal intensive care disposable devices for $3.3 million, and milestone payments of up to $400,000. CAS said it wants to focus on its core cerebral oximetry business. More

> Former Advanced Medical Optics CEO James Mazzo requested a stay until an upcoming Supreme Court case about insider trading is resolved. The jury trial in his insider trading case is slated to commence on July 19. Mazzo was indicted on 13 counts of insider trading, 13 counts of tender offer fraud and one count of securities fraud in 2014. More

Biotech News

@FierceBiotech: Pitt team redesigns an epilepsy drug, from FierceBiotechResearch. Item | Follow @FierceBiotech

@JohnCFierce: Sanofi-Genzyme helps cancer biotech ImmuneXcite close $8.6M financing round. News | Follow @JohnCFierce

> Aveo hit with $4M SEC fraud penalty, feds set out to bar former execs for deception. Article

> Newron faces further FDA delay for Parkinson's drug as regulator demands addiction evidence. Story

Pharma News

@FiercePharma: Aduro, UC Berkeley team up in $7.5M immunotherapy and vaccine initiative. FierceVaccines story | Follow @FiercePharma

@EricPFierce: Construction begins on Novo Nordisk's first US, API plant and first outside of Denmark. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI: Shire scores a patent victory for Lialda, but Bass-spurred PTO review looms. Item | Follow @CarlyHFierce

> Valeant pitches deadline delays to creditors in debt rescue plan. Report

> Reuters: Turkish whistleblower accuses Novartis of bribing providers to boost scripts. More

> Novartis follows brand offloading trend, selling drugs in Japan to Sun. Article

Biotech Research News

> TSRI/Salk collaboration finds two unique enzymes that may control diabetes and inflammation. Item

> Johns Hopkins scientists help explain why cancer stem cells survive in low oxygen. Report

> Gene targeting reverses cardiac fibrosis in heart-failure models. Story

> Two-stage nanoparticle smart bomb targets lung, breast cancer cells. More

> Stanford team boosts human cells' resistance to viruses with discarded GSK drug. Article

Vaccines News

> Sanofi Pasteur releases early results from next-gen flu vax tech. Story

> Aduro, UC Berkeley team up in $7.5M immunotherapy and vaccine initiative. More

> GSK planning combo vax launches in India, report says. Article

> DOD awards UC Irvine $8M to develop Q fever vaccine. News

Pharma Marketing News

> Keryx anemia med Auryxia trounces placebo in study aimed at big new use. News

> Brand matters: Interbrand's best in pharma ranks Pfizer, Roche and Merck at top. More

> WPP Group buys CMI healthcare and pharma media agency. Report

> Gilead meds face little threat from hep C rivals Merck, BMS and AbbVie: analyst. Story

> Teva goes for the absurd in latest opioid addiction video series. Article